BioArctic AB
BIOA-B.ST
Get informed when a big investor buys or sells
+ FollowMarket Cap$26.17B
Close$
Share Statistics
| Market cap | $26.17 Billion |
|---|---|
| Enterprise Value | $25.19 Billion |
| Dividend Yield | $2.00 (0.68%) |
| Earnings per Share | $11.55 |
| Beta | -0.69 |
| Outstanding Shares | 88,724,485 |
Return
| Return on Equity | 5.28% |
|---|---|
| Return on Assets | 3.78% |
| Return on Invested Capital | 9.53% |
Valuation & Multiples
| P/E Ratio | 248.24 |
|---|---|
| PEG | -222.5 |
| Price to Sales | 27.11 |
| Price to Book Ratio | 13.55 |
| Enterprise Value to Revenue | 25.14 |
| Enterprise Value to EBIT | 124.08 |
| Enterprise Value to Net Income | 238 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 26, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
$226.77 M
Average shareholder expectationNext Earnings Call
Expected Date
November 25, 2026
EPS Estimate
$0.24
Average shareholder expectationRevenue Estimate
$260.44 M
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About BioArctic AB
150 employees
CEO: Gunilla Christina Osswald BioArctic AB (publ) develops biological drugs for patients with central nervous system disorders in Sweden. It engages in the research and development of innovative biological drugs, such as antibodies that address high unmet medical nee...